Return to homepagePandemic Pact

Randomized trial of Covid-19 chemoprophylaxis in healthcare professionals (COVIDAXIS trial)

  • Funded by Institut Pasteur International Network (IPIN)
  • Total publications:0 publications

Grant number: COVIDAXIS trial

Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    Institut Pasteur International Network (IPIN)

  • Principal Investigator

    N/A

  • Research Location

    France

  • Lead Research Institution

    N/A

  • Research Priority Alignment

    N/A

  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Clinical trials for disease management

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Randomized Controlled Trial

  • Broad Policy Alignment

    Pending

  • Age Group

    Adults (18 and older)

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Hospital personnelUnspecified

Abstract

Objective: To determine whether a two months treatment with hydroxychloroquine (HCQ) or Lopinavir / ritonavir (LPV / r) reduces the incidence of symptomatic or asymptomatic infections with SARS-CoV-2, compared to their placebo, in healthcare professionals exposed to the virus.In the absence of specific antiviral treatment, particular attention must be paid to prevention. Individual protective equipment can be insufficiently protective, including for healthcare professionals.If this trial confirms the efficacy of either drug, a chemoprophylaxis strategy could be extended to other populations highly exposed to SARS-CoV-2 or at risk of severe forms of Covid-19 while waiting for other preventive tools, vaccines in particular, to become available.